APAC Ovarian Cancer Diagnostics & Therapeutics Market Size Market Trends

Market Trends of APAC Ovarian Cancer Diagnostics & Therapeutics Industry Size

Positron Emission Tomography is Expected to Hold a Significant Market Share Over the Forecast Period

• The rise in demand for positron emission tomography (PET) analysis in the diagnosis of ovarian cancer and the rising initiatives from the key market players are the factors responsible for driving the growth of the segment.
• According to the study published in Quantitative Imaging in Medicine and Surgery in March 2021 in China, PET/CT (computed tomography) scans accurately predicted peritoneal metastases with high sensitivity (84.2%), specificity (87.0%), and accuracy (85.1%) in advanced ovarian cancer before surgery. Such studies show the importance of PET scanning for ovarian cancer, thereby leading to increased adoption and driving segment growth.
• The huge investments by universities for the procurement of PET scanners are one of the factors driving the market growth. For instance, in March 2021, a USD 15 million project was proposed by the University of Sydney in a joint venture with the Northern Sydney Local Health District to procure a total-body PET scanner in Australia. This TB-PET scanner project will revolutionize Australia's biomedical imaging capabilities, deliver improved patient outcomes, and boost medical and health science research programs, driving market growth.
• Many radioisotopes and nuclear imaging equipment manufacturers are developing advanced technology for PET imaging for cancer and other diseases, also boosting the studied market. For instance, in May 2021, United Imaging, a China-based company involved in medical imaging and radiotherapy equipment, launched its uExcel Technology Platform for PET/CT at the China International Medical Equipment Fair (CMEF). Therefore, the rising innovative technologies in PET scanning help in the increased adoption of these scanners for ovarian cancer, driving the market growth.
• Hence, factors such as rising initiatives from key market players, such as investments and launches, are responsible for driving the growth of the market studied in the forecast period.

China is Expected to Hold a Healthy Share in the Market Over the Forecast Period

• The major factors fueling the market growth in the country are the increasing burden of ovarian cancer disorder, the growing focus on research and development of effective cancer therapies, and the rising number of product approvals, along with increasing investment.
• The rising incidence of ovarian cancers in the country is anticipated to drive market growth. For instance, in March 2021, a research study published in BMC Women's Health stated that the incidence and mortality of ovarian cancer have shown a fast-increasing trend in China. Hence, increasing ovarian cancer will increase the demand for diagnostics and therapeutics, which will increase the market growth in the region.
• Also, the research and developments accompanied by drug approvals in China are expected to drive market growth in the country due to the increased availability of ovarian cancer therapeutics. For instance, in May 2021, BeiGene, Ltd. received conditional approval from the China National Medical Products Administration (NMPA) for the treatment of patients with germline BRCA (gBRCA) mutation-associated recurrent advanced ovarian, fallopian tube, or primary peritoneal cancer. Furthermore, in May 2022, Zai Lab Limited presented the analysis of the Phase III PRIME study exploring the efficacy of niraparib maintenance therapy for patients in China with advanced ovarian cancer based on their response to first-line platinum-based chemotherapy.
• Hence, the abovementioned factors, such as the increasing incidence of ovarian cancers and rising approvals of ovarian cancer drugs in China, are expected to increase market growth in the region.